Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, after a major profit ...

All three major U.S. indexes finished in the red, after a disappointing services-sector report and tariff news weighed on investor sentiment. The ISM services-sector index provided another sign that ...

Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S ...

Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...

Investing.com -- Hims & Hers Health (NYSE: HIMS) stock edged lower on Tuesday, extending its 10% decline following disappointing earnings, as Novo Nordisk (NYSE: NVO) announced 14 new lawsuits ...

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

European shares closed higher on Tuesday, buoyed by better-than-expected corporate earnings and renewed optimism that the ...

Novo Nordisk (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than ...

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...